MAP3K1 Loss-of-Function Mutation

CI-VAR-00002517Explore in graph →CIViC 5016

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
MAP2K4 loss-of-function Mutation OR MAP3K1 Loss-of-Function Mutation	Selumetinib	Predictive	D	Supports Sensitivity Response	3	submitted	EID12141 In this study, sensitivity to MEK inhibitors was evaluated in multiple cancer models harbouring MAP3K1 and MAP2K4 loss-of-function mutations. In in-vitro experiments, two breast cancer cell lines, MDA… (full text at CIViC) PMID 29795445 · Xue et al., 2018 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.